Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms LBL 043, LBL043 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), LILRB4 inhibitors(Leukocyte immunoglobulin-like receptor subfamily B member 4 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | China | 30 Apr 2025 | |
Chronic Myelogenous Leukemia | Preclinical | China | 10 Apr 2024 | |
Treatment related acute myeloid leukaemia | Preclinical | China | 14 Mar 2024 |